Supernus Pharmaceuticals, Inc.
General ticker "SUPN" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $2.8B (TTM average)
Supernus Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -20.5%.
Estimated limits based on current volatility of 2.8%: low 38.87$, high 41.19$
Factors to consider:
- Total employees count: 778 (+15.4%) as of 2025
- Top business risk factors: Commercial success risk, Market competition, Reimbursement policies, Regulatory and compliance, Manufacturing dependency
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [38.54$, 57.87$]
- 2026-12-31 to 2027-12-31 estimated range: [36.93$, 56.62$]
Financial Metrics affecting the SUPN estimates:
- Positive: with PPE of 15.7 at the end of fiscal year the price was neutral
- Negative: Operating cash flow per share per price, % of 1.64 <= 2.37
- Positive: -13.52 < Operating profit margin, % of -7.97
- Positive: Inventory ratio change, % of 2.70 <= 4.02
- Positive: 69.38 < Shareholder equity ratio, % of 73.09 <= 81.92
- Positive: Industry inventory ratio change (median), % of -0.31 <= 0
- Negative: negative Industry operating income (median)
- Positive: Interest expense per share per price, % of 0 <= 0
Short-term SUPN quotes
Long-term SUPN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $607.52MM | $661.82MM | $718.95MM |
| Operating Expenses | $612.79MM | $580.15MM | $781.24MM |
| Operating Income | $-5.27MM | $81.67MM | $-62.28MM |
| Non-Operating Income | $8.04MM | $16.20MM | $13.25MM |
| Interest Expense | $2.42MM | $0.00MM | $0.00MM |
| R&D Expense | $91.59MM | $108.80MM | $106.23MM |
| Income(Loss) | $2.77MM | $97.87MM | $-49.03MM |
| Taxes | $1.45MM | $24.00MM | $-10.48MM |
| Net Income(Loss)* | $1.32MM | $73.86MM | $-38.55MM |
| Stockholders Equity | $921.52MM | $1,035.73MM | $1,061.71MM |
| Inventory | $77.41MM | $54.29MM | $82.39MM |
| Assets | $1,277.67MM | $1,368.07MM | $1,452.65MM |
| Operating Cash Flow | $111.08MM | $171.95MM | $47.33MM |
| Capital expenditure | $0.55MM | $0.72MM | $1.34MM |
| Investing Cash Flow | $268.73MM | $-189.87MM | $4.11MM |
| Financing Cash Flow | $-397.88MM | $12.19MM | $9.13MM |
| Earnings Per Share** | $0.02 | $1.34 | $-0.68 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.